Last updated on February 2019

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)


Brief description of study

THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin-associated amyloidoses (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate.

The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.

Detailed Study Description

n/a NA

Clinical Study Identifier: NCT00628745

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Advocate Christ Medical Center
Oak Lawn, IL United States
  Connect »

Pfizer CT.gov Call Center

Clinical Research Office
Oak Lawn, IL United States
  Connect »

Pfizer CT.gov Call Center

University of Chicago Medical Center IRB
Chicago, IL United States
8.86miles
  Connect »

Pfizer CT.gov Call Center

University of Chicago Medical Center
Chicago, IL United States
8.86miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.